COMMON INITIAL DOSING REGIMENS

• A common regimen involves taking one capsule daily with food. Some protocols use cycling strategies (e.g., 5 days on, 2 days off) to reduce the risk of receptor downregulation or adverse effects. Treatment duration may be continuous or repeated in monthly blocks based on individual response.

MECHANISM OF ACTION

• OS-01 is a proprietary, synthetic peptide designed to target senescent cells—aging or damaged cells that contribute to chronic inflammation and tissue dysfunction. Unlike the topical formulation, which acts locally on skin tissue, the oral form is intended to deliver systemic effects.

• OS-01 is believed to modulate gene expression associated with senescence markers such as p16^INK4a, reduce SASP (senescence-associated secretory phenotype) signaling, and promote DNA repair mechanisms. It may also help regulate oxidative stress and improve mitochondrial function throughout various tissues.

COMMON SIDE EFFECTS

• General: Mild headache, nausea, or fatigue during initial use.

• Gastrointestinal: Upset stomach, bloating, or soft stools.

• Dermatologic: Rare reports of transient acne or skin dryness during metabolic shifts.

• Neurologic: Vivid dreams or mood changes in sensitive individuals.

• Rare: Allergic reaction or elevated liver enzymes (theoretical).

CONTRAINDICATIONS

• Absolute: Known hypersensitivity to OS-01 or any excipients.

• Relative: Use with caution in individuals with autoimmune conditions, chronic liver disease, or those taking immunosuppressants. Not recommended in pregnancy or breastfeeding due to lack of safety data.

COMPARISON WITH OTHER AGENTS

• Topical OS-01: The topical version targets skin cells locally, while the oral capsule is designed for systemic senescence modulation. Oral use may provide benefits across organs and tissues beyond the skin.

• NAD+ boosters (NMN, NR): These support mitochondrial function but do not directly target cellular senescence. OS-01 may complement these agents for broader aging pathway coverage.

• Rapamycin: Both are used in anti-aging protocols, but rapamycin acts on mTOR inhibition and immune modulation, while OS-01 works through peptide signaling and cellular repair mechanisms.

EXPERIMENTAL TREATMENT DISCLAIMER:

• OS-01 (oral capsule) is not FDA-approved for any indication. Its use is experimental. While it is being studied for systemic anti-aging and senotherapeutic effects, clinical evidence in humans remains limited. Long-term safety and efficacy are unknown. The patient acknowledges the investigational nature of this therapy and assumes all associated risks.

MORE INFORMATION

• FDA Safety Data Sheet not available (experimental peptide).